spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Y-90 

 HSMN NewsFeed - 25 Mar 2024
Sirtex Medical Appoints Matt Schmidt as New Chief Executive Officer and Board of Directors Member
Devices Oncology Personnel
 HSMN NewsFeed - 9 Feb 2022
Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres(R) Y-90 resin microspheres in China from the National Medical Products Administration
Devices Oncology Regulatory
 HSMN NewsFeed - 11 Oct 2021
Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres(R) Y-90 resin microspheres in China
Devices Oncology
 HSMN NewsFeed - 22 Mar 2021
Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma
Devices Oncology
 HSMN NewsFeed - 18 Mar 2021
Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres
Devices Oncology FDA
 HSMN NewsFeed - 9 Dec 2020
Sirtex Medical announces strategic investment in BlackSwan Vascular, Inc.
Devices Oncology Venture Capital
 HSMN NewsFeed - 3 Jun 2020
Sirtex Medical appoints Dr. Mark A. Turco as Global Chief Medical Officer and EVP of Research & Development
Devices Oncology Personnel
 HSMN NewsFeed - 20 Nov 2018
Boston Scientific Announces Recommended Offer to Acquire BTG plc.
Devices Interventional Oncology Mergers & Acquisitions
 HSMN NewsFeed - 30 Jan 2018
Varian Signs Agreement to Acquire Sirtex
Devices Oncology Mergers & Acquisitions
 HSMN NewsFeed - 3 Jul 2017
New Analysis Reveals First-Line Treatment Data on SIR-Spheres(R) Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer
Devices Oncology
 HSMN NewsFeed - 24 Apr 2017
SIR-Spheres(R) Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
Devices Oncology
 HSMN NewsFeed - 11 Oct 2016
New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)
Devices Oncology
 HSMN NewsFeed - 25 Aug 2016
Sirtex Medical Inc. Announces 19 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres in Fiscal Year 2016
Devices Oncology
 HSMN NewsFeed - 1 Jul 2016
Patients with Colorectal Cancer Liver Metastases Had Significantly Greater Depth of Tumour Response to SIR-Spheres(R) Y-90 resin microspheres, New SIRFLOX Analysis Shows
Devices Oncology
 HSMN NewsFeed - 31 Mar 2016
SIR-Spheres(R) Y-90 Resin Microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says
Devices Oncology
 HSMN NewsFeed - 23 Feb 2016
SIRFLOX Study Published in Journal of Clinical Oncology
Devices Interventional Radiology Oncology
 HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals
 HSMN NewsFeed - 13 Aug 2015
Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres in Fourth Quarter
Devices Oncology Interventional
 HSMN NewsFeed - 17 Mar 2015
Sirtex Reports Preliminary SIRFLOX Study Results
Devices Drug Delivery Oncology
 HSMN NewsFeed - 30 Jul 2013
TheraSphere(R) Recommended by the National Institute for Health and Care Excellence (NICE) for the Treatment of Primary and Secondary Liver Cancer
Devices Oncology
 HSMN NewsFeed - 30 May 2013
SIR-Spheres(R) microspheres as Effective and Safe in the Elderly as they are in Younger Patients with Colorectal Liver Metastases According to Data Released at ASCO Annual Meeting
Devices Drug Delivery Oncology
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2012
Nordion Announces Europe-Focused Phase III Clinical Trial for TheraSphere(R) Liver Cancer Treatment
Devices Oncology
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons
 HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jun 2010
Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 9 Aug 2007
Review Examines the Use of Sirtex's SIR-Spheres(R) Microspheres in Patients with Hepatic Colorectal Cancer Metastases
Devices Oncology
 HSMN NewsFeed - 24 Jan 2007
Molecular Insight Pharmaceuticals, Inc. Acquires Clinical Stage, Targeted Radiotherapeutic Candidate Onalta(TM) (Formerly OctreoTher(TM))
Biopharmaceuticals Oncology Licensing
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.